牛牛AI助理已提取核心訊息
Heart Test Laboratories, Inc. (HSCS), a Texas-based medical technology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 34,684,859 shares of its common stock. The shares include those previously issued to certain selling stockholders and those that may be issued to Lincoln Park Capital Fund, LLC pursuant to a purchase agreement. The company will not receive proceeds from the selling stockholders' shares, except for any proceeds from the exercise of warrants. However, proceeds from the sale of shares to Lincoln Park will be used for working capital and general corporate purposes. The shares are being offered through a prospectus, and the offering will be made only by means of the prospectus. The registration statement includes details about the company's financials, risks, and the terms of the offering. The shares of common stock are listed on the Nasdaq Capital Market under the symbol 'HSCS'.
Heart Test Laboratories, Inc. (HSCS), a Texas-based medical technology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 34,684,859 shares of its common stock. The shares include those previously issued to certain selling stockholders and those that may be issued to Lincoln Park Capital Fund, LLC pursuant to a purchase agreement. The company will not receive proceeds from the selling stockholders' shares, except for any proceeds from the exercise of warrants. However, proceeds from the sale of shares to Lincoln Park will be used for working capital and general corporate purposes. The shares are being offered through a prospectus, and the offering will be made only by means of the prospectus. The registration statement includes details about the company's financials, risks, and the terms of the offering. The shares of common stock are listed on the Nasdaq Capital Market under the symbol 'HSCS'.
總部位於德克薩斯州的醫療技術公司Heart Test Laboratories, Inc.（HSCS）已向美國證券交易委員會（SEC）提交了註冊聲明，可能出售多達34,684,859股普通股。這些股票包括先前向某些出售股東發行的股票，以及根據收購協議可能向林肯公園資本基金有限責任公司發行的股票。除行使認股權證的任何收益外，公司不會從出售股東的股票中獲得收益。但是，向林肯公園出售股票的收益將用於營運資金和一般公司用途。這些股票是通過招股說明書發行的，並且只能通過招股說明書進行發行。註冊聲明包括有關公司財務狀況、風險和發行條款的詳細信息。普通股在納斯達克資本市場上市，股票代碼爲 “HSCS”。
總部位於德克薩斯州的醫療技術公司Heart Test Laboratories, Inc.（HSCS）已向美國證券交易委員會（SEC）提交了註冊聲明，可能出售多達34,684,859股普通股。這些股票包括先前向某些出售股東發行的股票，以及根據收購協議可能向林肯公園資本基金有限責任公司發行的股票。除行使認股權證的任何收益外，公司不會從出售股東的股票中獲得收益。但是，向林肯公園出售股票的收益將用於營運資金和一般公司用途。這些股票是通過招股說明書發行的，並且只能通過招股說明書進行發行。註冊聲明包括有關公司財務狀況、風險和發行條款的詳細信息。普通股在納斯達克資本市場上市，股票代碼爲 “HSCS”。
有用
沒用
